These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 29727915)

  • 1. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
    Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
    Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
    Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
    Hallemeier CL; Zhang P; Pisansky TM; Hanks GE; McGowan DG; Roach M; Zeitzer KL; Firat SY; Husain SM; D'Souza DP; Souhami L; Parliament MB; Rosenthal SA; Lukka HR; Rotman M; Horwitz EM; Miles EF; Paulus R; Sandler HM
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1057-1065. PubMed ID: 30959123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.
    Narang AK; Trieu J; Radwan N; Ram A; Robertson SP; He P; Gergis C; Griffith E; Singh H; DeWeese TA; Honig S; Annadanam A; Greco S; DeVille C; McNutt T; DeWeese TL; Song DY; Tran PT
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):203-209. PubMed ID: 28094250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies.
    Feng F; Miladinovic B; Zhang K; Dignam JJ; Wang D; Yu M; Sandler H
    Eur Urol; 2023 Sep; 84(3):331-340. PubMed ID: 37393115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
    Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
    Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy.
    Patel MA; Kollmeier M; McBride S; Gorovets D; Varghese M; Chan L; Knezevic A; Zhang Z; Zelefsky MJ
    Radiother Oncol; 2019 Nov; 140():34-40. PubMed ID: 31177042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
    Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
    J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy.
    Fang LC; Merrick GS; Butler WM; Galbreath RW; Murray BC; Reed JL; Adamovich E; Wallner KE
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):992-6. PubMed ID: 20932674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
    Jeong JU; Nam TK; Song JY; Yoon MS; Ahn SJ; Chung WK; Cho IJ; Kim YH; Cho SH; Jung SI; Kang TW; Kwon DD
    PLoS One; 2021; 16(3):e0248461. PubMed ID: 33711055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.
    D'Amico AV; Xie W; McMahon E; Loffredo M; Medeiros S; Joseph D; Denham J; Kumar P; Bubley G; Sullivan M; Hellwig R; Carlos Vera J; Freter R; Jeffrey Baker W; Wong JY; Renshaw AA; Kantoff PW
    J Clin Oncol; 2021 Sep; 39(26):2938-2947. PubMed ID: 34197181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer.
    Wong RL; Duong MT; Tangen CM; Agarwal N; Cheng HH; Vogelzang NJ; Hussain M; Thompson IM; Quinn DI; Yu EY
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):486-493. PubMed ID: 32055002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
    Mahal BA; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    J Natl Compr Canc Netw; 2018 Jun; 16(6):727-734. PubMed ID: 29891524
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer.
    Lee TH; Pyo H; Yoo GS; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Bae BK; Park W
    J Med Imaging Radiat Oncol; 2024 Apr; 68(3):333-341. PubMed ID: 38477380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
    Kass-Iliyya A; Jovic G; Murphy C; Fisher C; Syndikus I; Jose C; Scrase CD; Graham JD; Nicol D; Sydes MR; Dearnaley D
    Eur Urol; 2018 Jun; 73(6):968-976. PubMed ID: 29307509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation.
    Geara FB; Bulbul M; Khauli RB; Andraos TY; Abboud M; Al Mousa A; Sarhan N; Salem A; Ghatasheh H; Alnsour A; Ayoub Z; Gheida IA; Charafeddine M; Shahait M; Shamseddine A; Gheida RA; Khader J
    Radiat Oncol; 2017 Sep; 12(1):149. PubMed ID: 28882187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.